Tachykinin receptor antagonists

A compound of Formula I:

• wherein:
• D1 is a C1-C3 alkane-diyl;
• D2 is CH or nitrogen;
• D4 is oxygen or sulfur;
• R1 is phenyl,
• which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy;
• R4 is a radical selected from the group consisting of:
• wherein
• A1, A2, A3, and A4, together with the atoms to which they are attached, form an unsaturated heterocyclic ring in which each of A1, A2, and A3 is independently CR7, nitrogen, which nitrogen is optionally substituted with R8, oxygen, or sulfur, and A4 is carbon or nitrogen, wherein only one of A1, A2, and A3 can be oxygen or sulfur;
• A5, A6, A7, and A8, together with the atoms to which they are attached, form an unsaturated carbocyclic or heterocyclic ring in which each of A5, A6, A7, and A8 is independently CR7 or nitrogen, wherein at least one of A5, A6, A7, and A8 must be CR7;
• each R7 is independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, substituted C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxycarbonyl, trifluoromethyl, trifluoromethoxy, and —NR9R10;
• R9 and R10 are each independently hydrogen, C1-C4 alkyl, or —C(O)—CH3, or R9 and R10, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;
• each R8 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, substituted C1-C4 alkyl, and C1-C3 cycloalkyl;
• R6 is C1-C4 alkyl, C3-C6 cycloalkyl, phenyl, or pyridyl,
• which phenyl or pyridyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, trifluoromethoxy, and —NR11R12;
• R11 and R12 are each independently hydrogen or C1-C4 alkyl, or R11 and R12, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;
• R5 is hydrogen, halo, trifluoromethyl, C1-C4 alkyl, C3-C6 cycloalkyl, furyl, thienyl, pyrrolyl, imidazolyl, —NR13R14, pyridyloxy, phenyl, phenoxy, phenylthio, anilino,
• which phenyl, phenoxy, phenylthio, or anilino group may be optionally substituted on the phenyl ring with one or two substituents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and —S(O)q(C1-C4 alkyl),
• or a radical selected from the group consisting of:
• wherein
• W is a bond, CHR15, O, NR15, or S(O)q;
• q is 0, 1, or 2;
• R15 is selected from the group consisting of hydrogen, C1-C4 alkyl, acetyl, carbamoyl, phenyl, benzyl, and —S(O)2CH3;
• Z1, Z2, and Z3 are each independently CH or nitrogen;
• R13 and R14 are each independently hydrogen or C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.